Novo Nordisk A/S (NYSE:NVO)
| 159.15 Delayed Data As of Mar 31 |  +1.06 / +0.67%Today’s Change | 95.02 Today|||52-Week Range 159.74 | +17.59% Year-to-Date |
Latest NVO News | Press Releases
Today’s Trading
| Previous close | 158.09 |
| Today’s open | 158.60 |
| Day’s range | 158.07 - 159.74 |
| Volume | 1,142,969 |
| Average volume (3 months) | 1,385,170 |
| Market cap | $261.6B |
Data as of 4:00pm ET, 03/31/2023
Growth & Valuation
| Earnings growth (last year) | +4.77% |
| Earnings growth (this year) | +28.06% |
| Earnings growth (next 5 years) | +18.15% |
| Revenue growth (last year) | +11.71% |
| P/E ratio | 44.7 |
| Price/Sales | 12.30 |
| Price/Book | 28.68 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| MRKMerck | +0.42 | +0.40% |
| ABBVAbbVie | +1.44 | +0.91% |
| PFEPfizer | +0.41 | +1.02% |
| LLYEli Lilly and Co | +2.62 | +0.77% |
Data as of 4:00pm ET, 03/31/2023
Financials
| Next reporting date | May 4, 2023 |
| EPS forecast (this quarter) | $1.10 |
| Annual revenue (last year) | $25.0B |
| Annual profit (last year) | $7.8B |
| Net profit margin | 31.38% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Bagsværd, Capital Region |
Forecasts
